Krystexxa Cleared For Refractory Gout, Could Reach Patients By Year's End
This article was originally published in The Pink Sheet Daily
Executive Summary
Despite black box warning for anaphylaxis and infusion reactions, label and risk plan are seen as "benign" by analysts.